Rigel Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Rigel Pharmaceuticals

05/03/2025 01:23

Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly adjusted earnings of 80 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of six analysts for the quarter was for earnings of 47 cents per share. Wall Street expected results to range from 13 cents to $1.10 per share.

Revenue rose 60.9% to $57.60 million from a year ago; analysts expected $51.73 million.

Rigel Pharmaceuticals Inc's reported EPS for the quarter was 80 cents​.

The company reported quarterly net income of $14.34 million.

Rigel Pharmaceuticals Inc shares had risen by 33.0% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 56.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is  "hold."

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.00

This summary was machine generated from LSEG data March 5 at 01:22 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
0.47
0.80
Beat
Sep. 30 2024
0.06
0.70
Beat
Jun. 30 2024
-0.29
-0.06
Beat
Mar. 31 2024
-0.29
-0.50
Missed